Tag: pharmaceutical industry
Obesity as disease: Who profits from the classification shift?
Max Moser argues in STAT News that obesity's reclassification as a disease has accelerated pharmaceutical development while raising questions about…
Longevity Science Attracts $5.2 Billion in Investment as Movement Shifts from Fringe to Mainstream
Global investment in longevity science reached $5.2 billion in 2024-2025 as the field transitions from niche research to mainstream commercial…
Submit Your Paper to GMJ
No APC until January 2027.